Immunization of Mice with Gamma-irradiated Brucella Neotomae and Its Recombinant Strains Induces Protection Against Virulent B. Abortus, B. Melitensis, and B. Suis Challenge

Overview

Journal Vaccine

Specialty Allergy & Immunology

Date 2010 Nov 27

PMID 21109033

Citations 16

Authors

Dina Moustafa

Virendra K Garg

Neeta Jain

Nammalwar Sriranganathan

Ramesh Vemulapalli

Affiliations

Soon will be listed here.

Abstract

Human brucellosis, a zoonotic disease of major public health concern in several developing countries, is primarily caused by Brucella abortus, Brucella melitensis, and Brucella suis. No brucellosis vaccine is available for human use. The aim of this study was to determine if Brucella neotomae, a bacterium not known to cause disease in any host, can be used for developing brucellosis vaccines. B. neotomae and its recombinant strains overexpressing superoxide dismutase and a 26 kDa periplasmic protein were rendered non-replicative through exposure to gamma-radiation and used as vaccines in a murine brucellosis model. All three vaccines induced antigen-specific antibody and T cell responses. The vaccinated mice showed significant resistance against challenge with virulent B. abortus 2308, B. melitensis 16 M, and B. suis 1330. These results demonstrate that the avirulent B. neotomae is a promising platform for developing a safe and effective vaccine for human brucellosis.

Citing Articles

Gamma-Irradiated Non-Capsule Group B Streptococcus Promotes T-Cell Dependent Immunity and Provides a Cross-Protective Reaction.

Zhi Y, Chen F, Cao G, Li F Pharmaceuticals (Basel). 2023; 16(2).

PMID: 37259463 PMC: 9961543. DOI: 10.3390/ph16020321.

Protection against virulent spp. by gamma-irradiated in BALB/c mice model.

Al-Mariri A, Al-Hallab L, Alabras R, Kherbik H, Khawajkiah M Clin Exp Vaccine Res. 2022; 11(1):53-62.

PMID: 35223665 PMC: 8844668. DOI: 10.7774/cevr.2022.11.1.53.

Ionizing Radiation Technologies for Vaccine Development - A Mini Review.

Bhatia S, Pillai S Front Immunol. 2022; 13:845514.

PMID: 35222438 PMC: 8873931. DOI: 10.3389/fimmu.2022.845514.

Assessment of microbiological correlates and immunostimulatory potential of electron beam inactivated metabolically active yet non culturable (MAyNC) Salmonella Typhimurium.

Praveen C, Bhatia S, Alaniz R, Droleskey R, Cohen N, Jesudhasan P PLoS One. 2021; 16(4):e0243417.

PMID: 33861743 PMC: 8051754. DOI: 10.1371/journal.pone.0243417.

Development of attenuated live vaccine candidates against swine brucellosis in a non-zoonotic B. suis biovar 2 background.

Aragon-Aranda B, de Miguel M, Lazaro-Anton L, Salvador-Bescos M, Zuniga-Ripa A, Moriyon I Vet Res. 2020; 51(1):92.

PMID: 32703299 PMC: 7376850. DOI: 10.1186/s13567-020-00815-8.

References

Vemulapalli R, Duncan A, Boyle S, Sriranganathan N, Toth T, Schurig G . Cloning and sequencing of yajC and secD homologs of Brucella abortus and demonstration of immune responses to YajC in mice vaccinated with B. abortus RB51. Infect Immun. 1998; 66(12):5684-91. PMC: 108718. DOI: 10.1128/IAI.66.12.5684-5691.1998. View

Cloeckaert A, Jacques I, de Wergifosse P, Dubray G, Limet J . Protection against Brucella melitensis or Brucella abortus in mice with immunoglobulin G (IgG), IgA, and IgM monoclonal antibodies specific for a common epitope shared by the Brucella A and M smooth lipopolysaccharides. Infect Immun. 1992; 60(1):312-5. PMC: 257538. DOI: 10.1128/iai.60.1.312-315.1992. View

Onate A, Vemulapalli R, Andrews E, Schurig G, Boyle S, Folch H . Vaccination with live Escherichia coli expressing Brucella abortus Cu/Zn superoxide dismutase protects mice against virulent B. abortus. Infect Immun. 1999; 67(2):986-8. PMC: 96417. DOI: 10.1128/IAI.67.2.986-988.1999. View

Gonzalez D, Grillo M, de Miguel M, Ali T, Arce-Gorvel V, Delrue R . Brucellosis vaccines: assessment of Brucella melitensis lipopolysaccharide rough mutants defective in core and O-polysaccharide synthesis and export. PLoS One. 2008; 3(7):e2760. PMC: 2453230. DOI: 10.1371/journal.pone.0002760. View

Araya L, Elzer P, Rowe G, Enright F, Winter A . Temporal development of protective cell-mediated and humoral immunity in BALB/c mice infected with Brucella abortus. J Immunol. 1989; 143(10):3330-7. View

Bricker B, Tabatabai L, Judge B, DEYOE B, Mayfield J . Cloning, expression, and occurrence of the Brucella Cu-Zn superoxide dismutase. Infect Immun. 1990; 58(9):2935-9. PMC: 313590. DOI: 10.1128/iai.58.9.2935-2939.1990. View

Sharif M, Tassiulas I, Hu Y, Mecklenbrauker I, Tarakhovsky A, Ivashkiv L . IFN-alpha priming results in a gain of proinflammatory function by IL-10: implications for systemic lupus erythematosus pathogenesis. J Immunol. 2004; 172(10):6476-81. DOI: 10.4049/jimmunol.172.10.6476. View

Datta S, Okamoto S, Hayashi T, Shin S, Mihajlov I, Fermin A . Vaccination with irradiated Listeria induces protective T cell immunity. Immunity. 2006; 25(1):143-52. DOI: 10.1016/j.immuni.2006.05.013. View

Schurig G, Sriranganathan N, Corbel M . Brucellosis vaccines: past, present and future. Vet Microbiol. 2002; 90(1-4):479-96. DOI: 10.1016/s0378-1135(02)00255-9. View

10.

Vemulapalli R, He Y, Boyle S, Sriranganathan N, Schurig G . Brucella abortus strain RB51 as a vector for heterologous protein expression and induction of specific Th1 type immune responses. Infect Immun. 2000; 68(6):3290-6. PMC: 97584. DOI: 10.1128/IAI.68.6.3290-3296.2000. View

11.

Limet J, Plommet A, Dubray G, PLOMMET M . Immunity conferred upon mice by anti-LPS monoclonal antibodies in murine brucellosis. Ann Inst Pasteur Immunol. 1987; 138(3):417-24. DOI: 10.1016/s0769-2625(87)80052-1. View

12.

Yingst S, Hoover D . T cell immunity to brucellosis. Crit Rev Microbiol. 2003; 29(4):313-31. DOI: 10.1080/713608012. View

13.

Blasco J, Diaz R . Brucella melitensis Rev-1 vaccine as a cause of human brucellosis. Lancet. 1993; 342(8874):805. DOI: 10.1016/0140-6736(93)91571-3. View

14.

Bundle D, Cherwonogrodzky J, Perry M . Structural elucidation of the Brucella melitensis M antigen by high-resolution NMR at 500 MHz. Biochemistry. 1987; 26(26):8717-26. DOI: 10.1021/bi00400a034. View

15.

Caroff M, Bundle D, Perry M, Cherwonogrodzky J, Duncan J . Antigenic S-type lipopolysaccharide of Brucella abortus 1119-3. Infect Immun. 1984; 46(2):384-8. PMC: 261543. DOI: 10.1128/iai.46.2.384-388.1984. View

16.

Magnani D, Harms J, Durward M, Splitter G . Nondividing but metabolically active gamma-irradiated Brucella melitensis is protective against virulent B. melitensis challenge in mice. Infect Immun. 2009; 77(11):5181-9. PMC: 2772552. DOI: 10.1128/IAI.00231-09. View

17.

Vemulapalli R, He Y, Cravero S, Sriranganathan N, Boyle S, Schurig G . Overexpression of protective antigen as a novel approach to enhance vaccine efficacy of Brucella abortus strain RB51. Infect Immun. 2000; 68(6):3286-9. PMC: 97582. DOI: 10.1128/IAI.68.6.3286-3289.2000. View

18.

Kahl-McDonagh M, Ficht T . Evaluation of protection afforded by Brucella abortus and Brucella melitensis unmarked deletion mutants exhibiting different rates of clearance in BALB/c mice. Infect Immun. 2006; 74(7):4048-57. PMC: 1489724. DOI: 10.1128/IAI.01787-05. View

19.

Elzer P, Jacobson R, Jones S, Nielsen K, Douglas J, Winter A . Antibody-mediated protection against Brucella abortus in BALB/c mice at successive periods after infection: variation between virulent strain 2308 and attenuated vaccine strain 19. Immunology. 1994; 82(4):651-8. PMC: 1414908. View

20.

Bradford M . A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72:248-54. DOI: 10.1016/0003-2697(76)90527-3. View